These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8840431)

  • 21. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
    Mandler R; Wu C; Sausville EA; Roettinger AJ; Newman DJ; Ho DK; King CR; Yang D; Lippman ME; Landolfi NF; Dadachova E; Brechbiel MW; Waldmann TA
    J Natl Cancer Inst; 2000 Oct; 92(19):1573-81. PubMed ID: 11018093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Importance of the conjugated antibody for the induction of selective effect of adriamycin conjugated with anti AFP monoclonal antibody and entrapped in liposomes against AFP producing tumors].
    Konno H; Kumai K; Tsubouchi T; Ishibiki K; Abe O; Tadakuma T; Yasuda T; Nagaike K; Hosokawa S; Sakaguchi S
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2213-7. PubMed ID: 2472119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.
    Tokuda Y; Ohnishi Y; Shimamura K; Iwasawa M; Yoshimura M; Ueyama Y; Tamaoki N; Tajima T; Mitomi T
    Br J Cancer; 1996 Jun; 73(11):1362-5. PubMed ID: 8645580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ; Jin CJ; Rha SY; Chung HC
    Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Cameron DA; Leonard RC
    J Natl Cancer Inst; 1999 Apr; 91(8):728-9. PubMed ID: 10218517
    [No Abstract]   [Full Text] [Related]  

  • 26. Doxorubicin-anti-carcinoembryonic antigen immunoconjugate activity in vitro.
    Richardson VJ; Ford CH; Tsaltas G; Gallant ME
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):633-40. PubMed ID: 2714340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.
    Szöllösi J; Balázs M; Feuerstein BG; Benz CC; Waldman FM
    Cancer Res; 1995 Nov; 55(22):5400-7. PubMed ID: 7585609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Killing effect of Photofrin-Herceptin immunoconjugate on tumor cell lines in vitro].
    Qian XY; Luo RC; Li LB; Liao WJ; Luo YL
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):975-8. PubMed ID: 16109553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-erbB-2 product.
    Li J; Lee SE; Belciug M; Ring DB; Kwok CS
    Chin Med J (Engl); 2000 Feb; 113(2):151-3. PubMed ID: 11775541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of doxorubicin-monoclonal antibody conjugate on human bladder cancer.
    Yu DS; Chu TM; Yeh MY; Chang SY; Ma CP; Han SH
    J Urol; 1988 Aug; 140(2):415-21. PubMed ID: 3398165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity.
    Chen L; Liu YH; Li YH; Jiang Y; Xie PL; Zhou GH; Li GC
    Int Immunopharmacol; 2014 Jan; 18(1):20-6. PubMed ID: 24239629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
    Meenakshi A; Kumar RS; Kumar NS
    Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts.
    Kondo Y; Chung YS; Sawada T; Inui A; Yamashita Y; Hirayama K; Nakata B; Ho JJ; Kim YS; Sowa M
    Jpn J Cancer Res; 1995 Nov; 86(11):1072-9. PubMed ID: 8567399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor.
    Ozawa S; Ueda M; Ando N; Abe O; Minoshima S; Shimizu N
    Int J Cancer; 1989 Jan; 43(1):152-7. PubMed ID: 2783415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15.
    Ballaré C; Portela P; Schiaffi J; Yomha R; Mordoh J
    Breast Cancer Res Treat; 1998 Jan; 47(2):163-70. PubMed ID: 9497104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of antibody-targeted chemotherapy with pingyangmycin on prostate cancer cells in vitro].
    Chen WZ; Zhang Y; Liang CS; Xie Y; Wen QQ; Gao X
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):406-8. PubMed ID: 18359702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
    Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
    Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.